Michal Mark Danieli

Dr. Michal Mark Danieli

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2023 in Biosensors
Verified
Journal Article
Open access
PDF file
OWOry Wiesel
Ory Wiesel
SSSookwhan Sung
Sookwhan Sung
AKAmit Katz
Amit Katz
RLRaya Leibowitz
Raya Leibowitz
JBJair Bar
Jair Bar
MDMichal Mark Danieli
Michal Mark Danieli
Lung cancer is the leading cause of cancer-related mortality worldwide. Early detection is essential to achieving a better outcome and prognosis. Volatile organic compounds (VOCs) reflect alterations in the pathophysiology and body metabolism processes, as shown in various types of cancers. The biosensor platform (BSP) urine test uses animals’ unique, proficient, and accurate ability to scent lung cancer VOCs. The BSP is a testing platform for the binary (negative/positive) recognition of the signature VOCs of lung cancer by trained and qualified Long–Evans rats as biosensors (BSs). The results of the current double-blind study show high accuracy in lung cancer VOC recognition, with 93% sensitivity and 91% specificity. The BSP test is safe, rapid, objective and can be performed repetitively, enabling periodic cancer monitoring as well as an aid to existing diagnostic methods. The future implementation of such urine tests as routine screening and monitoring tools has the potential to significantly increase detection rate as well as curability rates with lower healthcare expenditure. This paper offers a first instructive clinical platform utilizing VOC’s in urine for detection of lung cancer using the innovative BSP to deal with the pressing need for an early lung cancer detection test tool.

16 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
OWOry Wiesel
Ory Wiesel
TSTatiyana Suharev
Tatiyana Suharev
AAAlaa Kasem Awad
Alaa Kasem Awad
LALina Abzah
Lina Abzah
ALAdi Laser
Adi Laser
MDMichal Mark Danieli
Michal Mark Danieli
Background: Lung cancer is the leading cause of cancer-related mortality worldwide. Lung cancer screening and early detection resulted in a decrease in cancer-specific mortality; however, it introduced additional dilemmas and adherence barriers for patients and providers. Methods: Innovations such as biomolecular diagnosis and biosensor-based technology improve the detection and stratification of high-risk patients and might assist in overcoming adherence barriers, hence providing new horizons for better selection of screened populations. Conclusions: In the present manuscript, we discuss some of the dilemmas clinicians are currently facing during the diagnosis and treatment processes. We further highlight the potential benefits of a novel biosensor platform for lung cancer detection during the decision making process surrounding lung cancer.